← Patent-cliff monitor small molecule JESDUVROQ DAPRODUSTAT
Loss of exclusivity March 2038 latest FDA-listed patent expiry
Company GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD ENGLAND
Drug detail Brand name JESDUVROQ Active ingredient DAPRODUSTAT Strength 8MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval February 2023 Marketing status DISCN
Listed patents Patent Expires Type 11117871 March 2038 substance, product 11649217 March 2038 product 8324208 December 2028 substance, product 8815884 June 2027 product 8557834 June 2027 use U-1238 11643397 June 2027 substance
Regulatory exclusivity Code Expires NCE February 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.